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needed to assess the influence of each type of symptom
on different components of psychological well-being, ad-
ditional QoL domains which may be affected, and psy-
chosocial correlates which may mediate between symp-
toms and outcome in menopausal women.
PWM6
IMPACT OF POSTMENOPAUSAL HORMONE 
REPLACEMENT THERAPY ON RESOURCE 
UTILIZATION ASSOCIATED WITH ADVERSE 
EVENTS
Chawla AJ1, Kennedy ST1, Ohsfeldt RL2
1The MEDSTAT Group, Inc., Washington, DC, USA; 2Eli Lilly 
and Company, Indianapolis, IN, USA
Hormone replacement therapy (HRT) can be useful for
preventing osteoporosis and improving serum cholesterol
levels among postmenopausal women. However, post-
menopausal HRT is associated with minor adverse events,
such as abnormal vaginal bleeding and breast pain or dis-
comfort, and may be associated with increased risks of
breast and uterine cancer. 
OBJECTIVE: To compare resource utilization for uterine
and breast disease screening, diagnostic evaluation, and
treatment among postmenopausal HRT users to non-
HRT users, over a 2-year period. 
METHODS: The study uses 1993–1996 MarketScan®
data. Women at least 50 years old were identified as new
HRT users based on both an estrogen and a progestin claim
within 45 days of each other, with no evidence of either
therapy during the prior 6 months. The sample of HRT
users included 970 women. A random sample of 2236
women with no HRT use over the study period was se-
lected as a control group. 
RESULTS: HRT users were more likely than non-users to
have visits with each of the following diagnoses: postmeno-
pausal bleeding, metrorrhagia, dysfunctional or functional
uterine hemorrhage, or abnormal bleeding from the female
genital tract. HRT users were more likely to have uterine-
related procedures such as ultrasound or hysteroscopy,
and more likely to have some breast-related procedures,
such as mammography, ultrasound of the breast, biopsy of
breast, or drainage of cysts. 
CONCLUSIONS: Postmenopausal HRT recipients were
more likely to experience abnormal uterine bleeding and
to have procedures related to uterine bleeding. Future
evaluations of the cost-effectiveness of HRT as a long-
term prevention strategy should incorporate the costs of
resource utilization related to adverse events of HRT in
addition to its clinical benefits.
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COST-EFFECTIVENESS OF ESTROGEN 
REPLACEMENT THERAPY (ERT) ON THE 
PREVENTION OF OSTEOPOROSIS: 
SHORT-TERM VERSUS LONG-TERM THERAPY
Liu G, Kamath T, Lee G, Chung F, Chung J, Lee S, Na J, Ngo 
S, Park M, Senuma K, You C
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: To determine the cost-effectiveness of short-
term (5 years) versus long-term (10 years) ERT in post-
menopausal women, in reducing the incidence of hip frac-
tures. 
METHODS: Data were derived from previously pub-
lished articles on the effect of ERT in the reduction of hip
fractures and long-term complications such as breast can-
cer and endometrial cancer in postmenopausal women.
Rate of reduction in hip fractures was used as a measure
of prevention of osteoporosis. From previous articles, we
obtained probabilities and costs of procedures associated
with hip fracture, drug therapy, and long-term complica-
tions. The cost of therapy included only the direct costs
(including costs to treat complications resulting from
ERT such as breast cancer and endometrial cancer) since
this study was performed from a third-party payer’s per-
spective. The effectiveness measure was calculated as the
life-years gained from reduction in hip fractures. 
RESULTS: The net cost of 5-year ERT was $7433 and
for the 10-year therapy the net cost was $5445. The life-
years saved increased from .06 life-years saved (LY) with
5-year therapy to 0.14 LY with 10-year therapy. Without
further analysis, it was seen that the 10-year therapy
costs less and patients survive longer. 
CONCLUSION: Our study showed that long-term estro-
gen replacement therapy (10 years) was more cost-effective
than short-term therapy (5 years) in the treatment of os-
teoporosis in postmenopausal women and hence women
who were on ERT should be placed on it for 10 years.
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COST-EFFECTIVENESS OF VIAGRA 
VERSUS MUSE IN THE TREATMENT OF MALE 
ERECTILE DYSFUNCTION
Liu G, Kamath T, Cahili R, Fukui C, Goodman A, Hong J, 
Huang I, Lai J, Le R, Le S, Su A, Tran S, Tran T, Tsai B
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: To determine if Viagra was more cost-ef-
fective than Muse in the treatment of male erectile dys-
function. 
METHODS: Data on the efficacy of the two drugs was
obtained from previous studies on these drugs. Our study
period was set at 6 months. The study patients were
males aged between 18–75 years, in a stable relationship
with a female partner for at least 6 months, and diag-
nosed with erectile dysfunction for 6 months or longer.
The patients received either Viagra or Muse for treatment
of their erectile dysfunction. The study was performed
from a payer’s perspective and hence only included cost
of the drug and related hospitalizations. Data were also
derived from clinicians about the probability of compli-
cations, and from some hospitals to obtain the costs of
hospitalizations and emergency room visits. The effec-
tiveness measure in our study was the percentage of suc-
cessful intercourse at the end of the 6-month period. 
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RESULTS: The percentage of successful intercourse with
Viagra treatment was 72% while with the Muse treat-
ment, it was 63%. The incremental cost-effectiveness ra-
tio was calculated to be $628 per successful intercourse. 
CONCLUSION: Our results indicate that one additional
successful intercourse would cost $628 more when switch-
ing from Muse to Viagra. If using an average cut-off ratio
of $50 per successful event which was estimated directly
from a group of patients’ preferences as a willingness-to-
pay measure, we concluded that Viagra could not be con-
sidered to be cost-effective compared to Muse in the
treatment of male erectile dysfunction.
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ECONOMIC EVALUATION IN REAL-LIFE 
SETTING OF ALPHA-BLOCKERS VERSUS 
FINASTERIDE VERSUS SERENOA REPENS
IN THE TREATMENT OF BENIGN
PROSTATIC HYPERPLASIA
Schmitt C1, Aussage P1, Berdeaux G2
1ARCOS, Issy-les-Moulineaux, France; 2Pierre Fabre 
Médicament, Boulogne-Billancourt, France
OBJECTIVE: To identify prescription patterns and costs
of benign prostatic hyperplasia (BPH) therapy in a real-
life setting. 
METHODS: Records from the French primary care data-
base Thales were screened to identify patients who initi-
ated a therapy with either -blockers (A) [alfuzosin, tam-
sulosin, terazosin] or finasteride (F), or a lipido-sterolic
extract of Serenoa repens (Px), between June 1996 and
May 1997 and who were followed up for at least 12
months. Patients with a diagnosis of prostatic cancer were
excluded. Endpoints were: 1-year BPH related costs, con-
comitant medication costs and total healthcare costs ac-
cording to the French National Health System. In order
to adjust for differences of socioeconomic and clinical
characteristics between treatment groups, endpoints were
analyzed using the propensity score method. 
RESULTS: 601 patients were identified in group A, 264 in
group F, and 315 in group Px. The median age was 67
years. Groups were unbalanced as to age (P  0.01), hy-
pertension (P  0.05), and urological troubles (P  0.05):
A were prescribed to younger patients with less hyperten-
sion, while F was prescribed to patients with less urologi-
cal disturbances. Unadjusted annual total healthcare costs
per patient were $1130 for group A, $1360 for group F,
and $1120 for group Px. Difference between A and Px re-
mained after adjustment ($36), due to a lower price of Px
and to reduced concomitant prescription costs. Difference
between F and Px also remained after adjustment ($242),
due to the previous reasons but also to a shorter treatment
duration. 
CONCLUSION: In real-life clinical practice, annual total
healthcare costs were lower when initiating a treatment
for BPH with Serenoa repens than with finasteride and
-blockers.
USE OF OUTCOMES RESEARCH (ECONOMIC, 
CLINICAL, HUMANISTIC) IN HEALTHCARE 
DECISION-MAKING
PPO1
THE ROLE OF QUALITY OF LIFE INFORMATION 
IN MANAGED CARE DECISION-MAKING
Crawford B1, Dukes E2, Bailey L3, Evans C1
1MAPI Values, Boston, MA, USA; 2Astra Pharmaceuticals, 
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The role of quality of life information in influencing man-
aged care decision-making in the United States is not well
understood. Previous research has suggested that efficacy,
safety, and cost-effectiveness information is viewed with
the highest level of importance and quality of life informa-
tion is viewed as more supplemental in nature. 
OBJECTIVE: The purpose of this study was to gain an
understanding of how decision-makers view quality of
life information. In particular, 1) the current and future
use of the information was examined, 2) the usefulness
and understanding of several types of QoL instruments,
and 3) the perceived weaknesses and strengths of quality
of life research. 
METHODS: Forty-one pharmacy and managed care di-
rectors completed a questionnaire by telephone to elicit
their attitudes on QoL research in managed care deci-
sion-making. 
RESULTS: Respondents felt that disease-specific quality of
life instruments were most useful (mean rank of 1.90 on a
5-point scale; 1  most useful), patient utility measures
ranked 3.10 and generic quality of life measures 3.83. Re-
spondents were asked their level of familiarity (5-point
Likert scale) with 11 common, disease-specific and generic
measures. They were most familiar with the SF-36 (mean
rank 3.17) and least familiar with the EuroQoL (mean
rank 1.34). Respondents felt that the results of QoL evalu-
ations could not be generalized (51.2%) and suffered from
too many assumptions (53.7%). Most respondents (52.7%)
felt that the main strength of QoL studies was that they
consider the perspective of the patient. 
CONCLUSIONS: Familiarity with QoL research and in-
struments by MCO decision-makers is relatively low, and
research in the area suffers from broad acceptability. Fu-
ture work should be conducted to educate MCOs on the
usefulness of QoL evaluations.
PPO2
THE DEVELOPMENT OF A PRACTICAL 
PROVIDER PROFILING REPORT
Gevirtz F, Nash DB, Moxey ED, O’Connor JP, Turk B, 
Corrato R
Office of Health Policy and Clinical Outcomes, Philadelphia, 
PA, USA
Healthcare providers are under increasing pressure to doc-
ument their outcomes to managed care organizations, em-
